MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-14-2026
Grifols, S.A. Total Liabilities 2011-2026 | GRFS
Annual Total Liabilities Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.8 B | 13.5 B | 13.3 B | 11.9 B | 8.55 B | 8.7 B | 7.78 B | 7.29 B | 6.4 B | 6.3 B | 5.79 B | 3.75 B | 3.75 B | 4.14 B |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.5 B | 3.75 B | 8.14 B |
Quarterly Total Liabilities Grifols, S.A.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 11.9 B | - | - | - | 8.55 B | - | - | - | 8.7 B | - | - | - | 7.78 B | - | - | - | 7.29 B | - | - | - | 6.4 B | - | - | - | 6.3 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.9 B | 6.3 B | 8.13 B |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Amarin Corporation plc
AMRN
|
211 M | $ 14.67 | -0.07 % | $ 6.09 B |  Irlanda |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
7.24 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
110 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
53 M | $ 2.82 | 1.44 % | $ 283 M | USA |
 |
Avid Bioservices
CDMO
|
276 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.29 | -3.01 % | $ 329 M | Britain |
 |
CEL-SCI Corporation
CVM
|
14.1 M | $ 3.47 | -1.7 % | $ 221 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Denali Therapeutics
DNLI
|
144 M | $ 19.74 | -12.17 % | $ 3.25 B | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
68.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
4.1 M | $ 1.09 | -9.17 % | $ 22.4 M | Israel |
 |
Enochian Biosciences
ENOB
|
29.6 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
3.29 M | $ 2.06 | - | $ 118 M | USA |
 |
Esperion Therapeutics
ESPR
|
768 M | $ 2.85 | 3.26 % | $ 592 M | USA |
 |
Eton Pharmaceuticals
ETON
|
66 M | $ 23.45 | -1.64 % | $ 631 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
6.22 M | $ 1.32 | -5.2 % | $ 1.88 M | China |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 47.55 | 0.98 % | $ 4.28 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.45 | -1.77 % | $ 853 M | Canada |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |